| DB ID | MyCo_2972 |
| Title | Galactomannan Is a Biomarker of Fosmanogepix (APX001) Efficacy in Treating Experimental Invasive Pulmonary Aspergillosis |
| Year | 2019 |
| PMID | 31685475 |
| Fungal Diseases involved | Invasive pulmonary aspergillosis |
| Associated Medical Condition | None |
| Genus | Aspergillus |
| Species | spp. |
| Organism | Aspergillus spp. |
| Ethical Statement | None |
| Site of Infection | None |
| Opportunistic invasive | Invasive |
| Sample type | Body fluid |
| Sample source | Bronchoalveolar lavage fluid (BALF) |
| Host Group | Animal |
| Host Common name | Mice |
| Host Scientific name | Mus musculus |
| Biomarker Name | GM |
| Biomarker Full Name | Galactomannan |
| Biomarker Type | Diagnostic |
| Biomolecule | Protein |
| Geographical Location | USA |
| Cohort | None |
| Cohort No. | None |
| Age Group | None |
| P Value | p<0.02 |
| Sensitivity | None |
| Specificity | None |
| Positive Predictive Value | None |
| MIC | None |
| Fold Change | None |
| Pathway | None |
| Disease Introduction Mechanism | Invasive pulmonary aspergillosis (IPA) is a serious fungal infection affecting immuno- compromised patients. Fosmanogepix (APX001) is a first-in-class antifungal prodrug that is currently in clinical development for the treatment of invasive fungal infections. Fosmanogepix is rapidly and completely metabolized by systemic phosphatases to the active moiety manogepix (MGX; previously APX001A), which targets the highly conserved fungal enzyme Gwt1. Gwt1 catalyzes an early step in glycosylphosphatidy-linositol (GPI) anchor biosynthesis, and inhibition of this enzyme has pleiotropic effects on cell wall integrity, biofilm formation, and fungal growth. |
| Technique | ELISA |
| Analysis Method | FDA Approved -Platelia Aspergillus ELISA |
| ELISA kits | ELISA Kit- Platelia Aspergillus |
| Assay Data | None |
| Validation Techniques used | FDA Approved -Platelia Aspergillus ELISA |
| Up Regulation Down Regulation | Positive |
| Sequence Data | None |
| External Link | None |
